Exposing Brachial Plexus: A Surgical Technique to Visualize Brachial Plexus in Neonatal Piglet

Executive Industry Relevance

This surgical technique enables precise anatomical mapping of the brachial plexus in a neonatal model, supporting target validation in neuroscience research. By providing reproducible exposure of neural structures, it facilitates mechanistic de-risking for therapeutic interventions targeting peripheral nerve injury or regeneration. The method enhances predictive confidence in preclinical models by establishing a standardized workflow for nerve visualization and assessment.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of neural architecture to clarify therapeutic targets in peripheral nervous system pathways.
• Operational Value: Supports biological de-risking through direct visualization of plexus integrity and nerve branch identification.
• Predictive Value: Enhances target confidence by allowing structural assessment before functional testing in injury or repair models.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream assays by ensuring consistent anatomical exposure.
• Operational Value: Promotes assay standardization and reproducibility through standardized dissection steps and landmark-based identification.
• Scalability: Supports platform reuse across studies requiring nerve injury modeling or neurite outgrowth evaluation.

Translational & Preclinical Research

• Translational Relevance: Uses a disease-relevant system with anatomical similarity to human brachial plexus for preclinical continuity.
• Mechanistic De-risking: Enables evaluation of nerve repair strategies by providing clear visualization of trunk, division, cord, and branch regions.
• Risk-Adjusted Advancement: Supports go/no-go decisions by allowing correlation of structural integrity with functional outcomes in injury models.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from early target validation through preclinical assessment, enabling structural confirmation before functional readouts in nerve injury or regeneration studies.

• Discovery Biology: Supports hypothesis testing and pathway clarification by exposing key anatomical regions of the brachial plexus for targeted intervention.
• Screening: Enhances assay readiness by delivering reproducible exposure of nerve branches for compound or biologic evaluation.
• Analytics: Enables quantitative assessment of nerve morphology, integrity, and spatial organization as a structural readout.
• Translational Research: Connects discovery to preclinical validation through a neonatal model with developmental relevance to human nerve structure.
• Enterprise Reuse: Establishes a reusable capability for neuroscience teams studying peripheral nerve anatomy, injury, or regeneration across multiple projects.

Operational & Enterprise Impact

• Scientific Value: Provides predictive confidence in target validation by reducing anatomical ambiguity in neural models.
• Operational Value: Ensures standardization and reproducibility through stepwise dissection and landmark-guided exposure.
• Strategic Value: Improves go/no-go decisions by enabling early structural assessment, reducing late-stage failure in nerve-targeted programs.
• Portfolio Impact: Supports risk-adjusted prioritization by allowing objective evaluation of nerve integrity before advancing therapeutic candidates.

Implementation Considerations

• Requires expertise in neonatal animal handling and microsurgical dissection techniques.
• Dependent on precision instrumentation including #10 scalpel, forceps, and scissors for tissue separation.
• Necessitates standardization across teams to ensure consistent identification of vertebral landmarks (C3 to T3) and plexus regions.
• Adaptation considerations include scaling the technique to other neonatal or juvenile models while maintaining anatomical fidelity.
• Practical limitations include the need for careful avoidance of vascular structures (e.g., cephalic and basilic veins) during blunt dissection.

Biopharma FAQs